By targeting both GLP1 and GIP receptors, Tirzepatide enhances insulin secretion and reduces glucagon secretion in a glucose-dependent manner, contributing to improved glycemic control. In addition to its glucose-lowering effects, tirzepatide has been associated with significant weight loss in clinical trials. This can be particularly beneficial for individuals with type 2 diabetes, as weight management is a crucial aspect of overall diabetes care. Like other newer diabetes medications, tirzepatide has undergone cardiovascular outcomes trials. These trials assess the impact of the medication on cardiovascular events, providing valuable information on the safety and potential cardiovascular benefits of the drug.